Impact of chronic emotions and psychosocial stress on glycemic control in patients with type 1 diabetes. Heterogeneity of glycemic responses, biological mechanisms, and personalized medical treatment
- PMID: 37858921
- DOI: 10.1016/j.diabet.2023.101486
Impact of chronic emotions and psychosocial stress on glycemic control in patients with type 1 diabetes. Heterogeneity of glycemic responses, biological mechanisms, and personalized medical treatment
Abstract
Many studies have clearly established that chronic psychosocial stress may sustainably worsen glycemic control in patients with type 1 diabetes mellitus (T1DMM), thus promoting diabetes complications. Chronic psychosocial stress may be due to: i) the long-term accumulation of stressful life events that require readjustment on the part of the individual (loosing friends, changing schools), and/or ii) exposure to severe chronic stressors (persistent difficulties and adversities of life). Whatever the reason, many studies have clearly established a positive correlation between chronic psychosocial stress and HbA1c levels. However, a small fraction of patients is minimally affected or not affected at all by chronic psychosocial stress. Conversely, positive life events can substantially improve glycemic control. Recent evidence suggests the existence of subpopulations that differ in personality traits, neurohormonal regulatory responses, and food intake behavior (increased or decreased). Better characterization of the clinical and neurohormonal differences between these subpopulations may help develop personalized treatment strategies in the future. In the near future, psychotherapeutic support and automated insulin delivery (AID) could alleviate chronic stress, prevent worsening glycemic control, and ease the burden of diabetes.
Keywords: Glycemic control; HbA1c; Psychosocial stress; Stress; Type 1 diabetes.
Copyright © 2023. Published by Elsevier Masson SAS.
Conflict of interest statement
Declaration of Competing Interest SF has received personal compensation for board participation and speaking fees from Novo Nordisk, Roche Diagnostics, Lifescan, Sanofi, Diabeloop and Eli Lilly, received Research support from MSD outside of this work; SF is employed by CERITD and is a shareholder of Diabeloop. PS has received honoraria for her participation in advisory boards for Eli-Lilly, Novo-Nordisk, Ypsomed, Orkyn, Timkl, and participation in symposia organized by Novo-Nordisk, Abbott Diabetes Care, Roche, Sanofi, and Insulet outside the submitted work. GC is employed by CERITD and is a shareholder of Diabeloop. LO and SB are employed by CERITD and have no conflict of interest to declare. PL has no conflict of interest to declare. The Epistress 1 study was carried out with CERITD's own funds.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical